Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide Observations From the PROTECT–TIMI-30 Trial by Kirtane, Ajay J. et al.
C
t
C
O
A
D
N
C
B
a
T
(
v
o
c
e
B
‡
H
P
p
s
h
t
P
f
M
c
c
P
a
Journal of the American College of Cardiology Vol. 47, No. 12, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Porrelates of Bleeding Events Among Moderate-
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OBJECTIVES We aimed to identify correlates of Thrombolysis In Mycocardial Infarction (TIMI)
major/minor bleeding among eptifibatide-treated patients undergoing percutaneous coronary
intervention (PCI).
BACKGROUND Evaluation of bleeding predictors among patients treated with glycoprotein IIb/IIIa receptor
inhibition might aid in the identification of targets to reduce bleeding risk.
METHODS Data were analyzed from 567 moderate- to high-risk PCI patients with non–ST-segment
elevation acute coronary syndrome (NSTEACS) treated with eptifibatide/reduced-dose
unfractionated heparin or eptifibatide/reduced-dose enoxaparin enrolled in the Randomized
Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and
Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents–Thrombolysis In
Myocardial Infarction-30 (PROTECT–TIMI-30).
RESULTS The incidence of significant bleeding was 3.2% with a median time to event of 7.0 h after the
first eptifibatide bolus. Increased age was the only independent correlate of bleeding events.
Among patients with reduced creatinine clearance (CrCl), lack of adjustment of the
maintenance infusion for CrCl 50 ml/min occurred frequently (15 of 33 patients, or 45%)
and was associated with a high rate of bleeding (20%). The association of CrCl with
bleeding appeared to be largely mediated by the incorporation of age in the estimation of
CrCl. Patient gender, Cr, weight, and the peak activated clotting time were not associated
with bleeding.
CONCLUSIONS Among NSTEACS PCI patients treated with eptifibatide, increased age was a significant
correlate of bleeding events and appeared to explain the association between low CrCl and
bleeding. The more widespread use of CrCl or other estimates of renal function over Cr may
lead to more appropriate dose adjustments of eptifibatide. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.0802374–9) © 2006 by the American College of Cardiology Foundation
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Ahe adjunctive use of platelet glycoprotein IIb/IIIa receptor
GPIIb/IIIa) inhibitors during percutaneous coronary inter-
ention (PCI) has been associated with improved clinical
utcomes (1– 4), primarily through a reduction in peripro-
edural ischemic events. Although GPIIb/IIIa inhibitors have
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ccepted September 8, 2005.een demonstrated to be beneficial in improving both short-
nd long-term outcomes, combined antithrombin and GPIIb/
IIa regimens have also been associated with a higher risk of
leeding (5,6).
Bleeding complications in PCI patients are associated
ith patient discomfort, prolonged hospital stays, increased
ost, and adverse outcomes (7,8). Given the demonstrated
fficacy of GPIIb/IIIa inhibitors in the prevention of
See page 2380
schemic events, particularly in higher risk patients with
cute coronary syndrome (ACS), further efforts to limit
leeding complications are critical to ensure the maximal
enefit from this drug class. To identify potential targets to
educe bleeding, we evaluated the correlates of bleeding
omplications among eptifibatide-treated patients enrolled in
he Randomized Trial to Evaluate the Relative Protection
gainst Post-PCI Microvascular Dysfunction and Post-PCI
schemia Among Anti-Platelet and Anti-Thrombotic Agents–
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IMI-30) of PCI in moderate- to high-risk non–ST-segment
levation acute coronary syndromes (NSTEACS).
ETHODS
ROTECT–TIMI-30 was a randomized multicenter trial
o evaluate the efficacy of eptifibatide in combination with
ow-dose heparin (unfractionated heparin [UFH] or enox-
parin) compared with bivalirudin monotherapy in high-
isk NSTEACS patients undergoing PCI (9). Patients
reated with a GPIIb/IIIa inhibitor or those with active
bnormal bleeding within 30 days of enrollment were
xcluded from the trial.
Patients in the eptifibatide/UFH arm were treated with a
tandard double bolus/infusion of eptifibatide (2) for 18 to
4 h plus a low-dose bolus of UFH (50 U/kg) with
dditional protocol-specified boluses to achieve a target
ctivated clotting time (ACT) of 200 to 250 s. Patients in
he eptifibatide/enoxaparin arm were treated with the same
egimen of eptifibatide plus 0.5 mg/kg intravenous enox-
parin. For both arms, the protocol specified that the dose
f the eptifibatide infusion was to be reduced to 1 g/kg/
in for patients with estimated creatinine clearance (CrCl)
f 50 ml/min. For patients who were being treated with
FH at screening, the UFH infusion was discontinued for
h before anticipated randomization unless the activated
Abbreviations and Acronyms
ACS  acute coronary syndrome
ACT  activated clotting time
Cr  creatinine
CrCl  creatinine clearance
GFR  glomerular filtration rate
GPIIb/IIIa  glycoprotein IIb/IIIa receptor
NSTEACS  non–ST-segment elevation acute
coronary syndrome
PCI  percutaneous coronary intervention
UFH  unfractionated heparinFigure 1. Relation of aartial thrombaplastin time was known to be 40 s or the
CT was 150 s. Study medications were administered
ollowing diagnostic coronary angiography and before PCI.
ll patients received aspirin before PCI and a thienopyri-
ine (clopidogrel or ticlopidine) if stenting was performed.
Bleeding end points were assessed by Thombolysis In
yocardial Infarction (TIMI) criteria. For the purpose of this
nalysis, we considered two end points: 1) the occurrence of
ny significant bleeding (the composite of TIMI major or
IMI minor bleeding); and 2) the occurrence of a blood
ransfusion within 48 h of randomization. All bleeding events
ere adjudicated by a blinded Clinical Events Committee.
For this analysis, CrCl was estimated using the Cockroft-
ault formula, and glomerular filtration rate (GFR) was
stimated using the abbreviated Modification of Diet in
enal Disease formula. The primary analyses were per-
ormed in the as-treated patient population with data
ooled from the UFH and enoxaparin groups; study results
ere no different in intent-to-treat analyses. Univariate
nalyses were performed using Fisher exact test and Wil-
oxon rank sum test. Covariates associated with bleeding
vents with p  0.2 were included in multivariable stepwise
election logistic regression models. When adjusting for
enal function, the individual components of the Cockroft-
ault formula (age, weight, 1/Cr, gender) were entered into
he model separately as covariates. First-order interaction
erms of these separate variables in the formula were
dditionally tested.
ESULTS
he incidence of significant bleeding was 3.2%. Of the 18
djudicated bleeding events, 4 were major bleeding events
nd 14 were minor. The primary locations of bleeding
ere as follows: five at access sites, three retroperitoneal,
ve gastrointestinal, and five coronary artery bypass
raft-related. Age (Fig. 1), low CrCl (Fig. 2), low GFR,
nd lower baseline hemoglobin were associated with signif-
cant bleeding in univariate analyses (Table 1). Althoughge and bleeding.
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PCI-Related Bleeding With Eptifibatide June 20, 2006:2374–9Figure 2. Relation of creatinine clearance (CrCl) and bleeding. IQ  interquartile range.Table 1. Correlates of Major or Minor Bleeding
Major/Minor Bleed
(n  18)
No Major/Minor Bleed
(n  549) p Value
Age (yrs) 71 (64,77) 59 (52,69) 0.01
Age 65 yrs (%) 72.2 36.3 0.01
Male gender (%) 50.0% 66.7% 0.20
Weight (kg) 79 (70,100) 89 (75,103) 0.21
CrCl (ml/min) 73.2 (55.6,90.4) 95.8 (71.6,121) 0.01
GFR (ml/min/1.73 m2) 67.4 (56.9,85.9) 78.5 (65.3,93.1) 0.03
Serum creatinine (mg/dl) 1.0 (0.9,1.2) 1.0 (0.8,1.1) 0.43
Prior MI (%) 23.5 22.4 1.0
Prior PCI (%) 33.3 24.7 0.41
Prior CABG (%) 11.1 7.3 0.64
Hypertension (%) 66.7 66.4 1.0
Cigarette smoker (%) 27.8 37.9 0.47
Diabetes (%) 16.7 36.9 0.09
Dyslipidemia (%) 72.2 54.9 0.16
Index event (%)
Unstable angina 55.6 51.8 0.81
Non–ST-segment elevation MI 44.4 48.2
ST-segment depression (%) 5.6 12.2 0.71
Prior aspirin (%) 77.8 57.5 0.10
Clopidogrel 6 h before randomization (%) 38.9 36.4 0.81
Treatment (%)
Eptifibatide/enoxaparin 50.0 47.5 1.0
Eptifibatide/heparin 50.0 52.5
Baseline hemoglobin (g/dl) 12.6 (11.9,13.0) 13.8 (12.5,14.9) 0.03
Peak ACT (s) 244 (223,310) 254 (214,291) 0.95
Use of closure device (%) 38.9 44.4 0.81
Numbers in parentheses are 25th and 75th percentile values.
ACT  activated clotting time; CABG  coronary artery bypass graft; CrCl  creatinine clearance; GFR  glomerular
filtration rate; MI  myocardial infarction; PCI  percutaneous coronary intervention.
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June 20, 2006:2374–9 PCI-Related Bleeding With EptifibatiderCl and GFR both were correlates of bleeding, serum Cr
as not.
Although all major bleeding events occurred among
atients treated with enoxaparin, the overall rate of signif-
cant bleeding was similar among patients treated with
FH versus enoxaparin (3.3% vs. 3.0%; p  NS). There
ere no significant differences in the rates of pretreatment
ith UFH or enoxaparin or in the rate of “cross-over” to a
ifferent study antithrombin between patients with and
ithout bleeding events (Table 2).
The majority of significant bleeding events occurred
everal hours after PCI, and half the bleeding events
ccurred 6 h after study drug administration (median
.0 h [interquartile range 3.1 to 14.0 h] after the first
ptifibatide bolus). The length of eptifibatide infusion was
horter among patients with bleeding events (median 5.3 h
s. 18.1 h among patients without bleeding; p  0.001),
uggesting that the infusion was terminated early in these
atients (Fig. 3). There was no significant difference in the
ime from the administration of the first eptifibatide bolus
o sheath removal among patients with bleeding events
ompared with those without bleeding events (1.6 h vs.
.9 h; p  0.60), and the median time from sheath removal
o significant bleeding was 5.7 h.
ssociation of eptifibatide dosing with bleeding events.
mong the 33 patients with CrCl 50 ml/min by the
ockroft-Gault formula who met criteria for a reduced-
ose eptifibatide infusion, 15 (45%) instead received the
ull-dose infusion. Appropriate dose adjustment of eptifi-
able 2. Rates of Bleeding Events and Transfusions According to
n (%)
Signific
Blee
(%)
rior heparin 222 (39%) 44
eparin within 12 h of randomization 193 (34%) 33
rior enoxaparin 172 (30%) 22
noxaparin within 12 h of randomization 5 (1%) 0
o prior antithrombin* 369 (65%) 67
onsistent antithrombin* 126 (22%) 22
nconsistent antithrombin* 72 (13%) 11
Based on antithrombin within 12 h of randomization.e
igure 3. Cumulative distribution function of duration of eptifibatide
nfusion in patients (pts) with bleeding. IQ  interquartile range.atide for low CrCl occurred less frequently among women
han among men (41% vs. 82%; p  0.03). Among patients
ho met criteria for a reduced-dose infusion, those who
eceived the full-dose eptifibatide infusion had a trend
oward lower serum Cr (1.3 vs. 1.5; p  0.08) but similar
eight and age.
The incidence of bleeding events among patients with
rCl 50 ml/min was 9.1% (3 of 33), and all bleeding
vents in this reduced CrCl group occurred in patients
reated with a full-dose eptifibatide infusion. There were no
leeding events among patients with reduced CrCl who
eceived the reduced-dose infusion. In the overall study
opulation, administration of a full-dose infusion to pa-
ients with reduced CrCl was associated with an over
ve-fold greater incidence of bleeding events compared with
he incidence of bleeding events among patients with CrCl
50 ml/min (Fig. 4).
ultivariable analysis. In multivariable analyses, advanced
ge was the only covariate independently associated with the
evelopment of bleeding complications (odds ratio [OR]
.6 [95% confidence interval (CI) 1.5 to 4.6] for each decade
ncrease in age; p  0.001). Age was the only component of
rCl that was independently associated with bleeding
omplications, whereas weight, 1/Cr, and gender were not.
ven after adjustment for the appropriate dosing of eptifi-
atide based on renal function, age remained an indepen-
ent correlate of bleeding (OR 2.1 [95% CI 1.2 to 3.5] for
ach decade increase of age; p  0.007). In a sensitivity
nalysis excluding bleeding events in patients with CrCl
50 ml/min who did not receive a reduced-dose eptifi-
atide infusion, age again remained the only independent
orrelate of bleeding events (OR 2.3 [95% CI 1.3 to 4.2] for
ach decade increase in age; p  0.004).
orrelates of blood transfusion. A blood transfusion was
dministered to 25 patients (4.4%), of which 15 had an
djudicated bleeding event (60%). Among the 10 additional
atients who received a transfusion but did not have a
ignificant bleeding event, three patients did not have any
leeding, and seven patients had bleeding that was adjudi-
ated as neither major nor minor. The baseline hemoglobin
as significantly lower among the group of patients receiv-
ng transfusions who did not have significant bleeding
or Antithrombin
No Significant
Bleed
(%) p
Transfusion
(%)
No
Transfusion
(%) p
40 0.63 52 39 0.21
34 1.0 44 34 0.29
31 0.61 12 31 0.05
1 1.0 0 1 1.0
65 56 65
22 1.0 28 22 0.58
13 16 13Pri
ant
dvents compared with patients receiving transfusions who
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PCI-Related Bleeding With Eptifibatide June 20, 2006:2374–9ad adjudicated bleeding events (11.0 vs. 12.6 g/dl; p 
.002). All three patients with significant bleeding events
ho did not receive a transfusion had minor bleeding
vents.
Age, female gender, lower CrCl, and lower baseline
emoglobin were the baseline characteristics significantly
ssociated with blood transfusion. The four patients with
rCl 50 ml/min who received a transfusion were all
atients who were treated with a full-dose eptifibatide
nfusion rather than a reduced-dose infusion (Fig. 4). In
ultivariable analyses, advanced age (OR 1.6 [95% CI 1.0
o 2.6] for each decade of age; p  0.04) and lower baseline
emoglobin (OR 0.5 [95% CI 0.4 to 0.7] for each g/dl
ncrease in hemoglobin; p 0.001) were the only covariates
ignificantly associated with blood transfusion. After adjust-
ent for the appropriate renal dosing of eptifibatide, age
nd lower baseline hemoglobin remained independent cor-
elates of transfusion.
ISCUSSION
valuation of correlates of bleeding among patients treated
ith eptifibatide during and after PCI may allow better
dentification of patients at risk and may inform strategies to
inimize bleeding risk. The strongest correlate of bleeding
vents in the present analysis was increased age. Although
rCl was also associated with bleeding, that appeared to be
argely related to the incorporation of age in the estimate of
rCl. In addition, administration of a full-dose eptifibatide
nfusion to patients with reduced CrCl was not uncommon
nd resulted in a greater incidence of bleeding complica-
ions. Finally, more than half of all bleeding events occurred
6 h after the initiation of eptifibatide. Thus, adjustment of
he eptifibatide infusion dose based upon a more complete
stimate of renal function as well as adjustment of the
Figure 4. Relation of dose adjustment of eptifibaturation of the eptifibatide infusion based upon patient risk Cactors may be two potential strategies to reduce bleeding.
Several risk factors for bleeding complications have been
escribed previously concerning patients treated with
PIIb/IIIa inhibitors undergoing PCI. Patients with ad-
anced age, renal insufficiency, female gender, peripheral
ascular disease, lower body weight, history of diabetes
ellitus, a greater dose of antithrombin, and an elevated
eak ACT have been shown to be at increased risk for
leeding (10 –13). Although the current analysis was a
etrospective analysis of a randomized clinical trial and was
ot adequately powered to evaluate all of these correlates,
ur findings reemphasize the greater risk of bleeding com-
lications among the elderly and those with impaired renal
unction.
Additionally, among patients with reduced CrCl, adminis-
ration of a full-dose eptifibatide infusion was associated with
greater incidence of bleeding events. These findings parallel
hose observed in the Can Rapid Risk Stratification of Unsta-
le Angina Patients Suppress Adverse Outcomes With Early
mplementation of the ACC/AHA Guidelines (CRUSADE)
egistry, in which the risk of bleeding requiring transfusion
as substantially increased among patients who were more
ikely to be administered excessive rather than appropriately
educed doses of GPIIb/IIIa inhibitors, including elderly
atients and those with renal insufficiency (14).
The majority of bleeding events occurred 6 h after
nitiation of eptifibatide or during the eptifibatide infusion.
lthough a majority of ischemic events occur during or early
fter the PCI procedure (15), it nonetheless remains unde-
ermined if early termination of the eptifibatide infusion
ould preserve or reduce the ischemia-related efficacy of the
gent. Therefore, prospective randomized trials are needed
o assess the relative efficacy and safety of a reduced duration
f eptifibatide infusion.
onclusions. Among NSTEACS PCI patients treated
ith eptifibatide, increased age was the only constituent of
fusion to bleeding. CrCl  creatinine clearance.rCl that was associated with the occurrence of bleeding
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June 20, 2006:2374–9 PCI-Related Bleeding With Eptifibatidevents. The use of serum Cr alone to adjust eptifibatide
osing may yield inadequate dose reductions, and use of
rCl or GFR may be preferable. Because half of the
bserved bleeding events occurred late, a reduced duration
f eptifibatide infusion may be another target to reduce
leeding and awaits evaluation in future studies.
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